CureVac, UK Enter COVID-19 Vaccine Collaboration
07:55 AM EST, 02/05/2021 (MT Newswires) -- CureVac (CVAC) said Friday it has entered into a collaboration with the UK government to develop and manufacture potential COVID-19 vaccines.
The agreement includes a potential 50 million initial dose supply, as well as manufacturing capabilities to rapidly produce large quantities of variant vaccines if and when needed over the next three years, CureVac said. Approved vaccines from the collaboration will be manufactured and distributed in the UK and its overseas and dependent territories, the German company added.
CureVac will work with the British Vaccines Taskforce (VTF) in the partnership to evaluate COVID-19 variants and develop potential messenger ribonucleic acid (mRNA) therapies against them.
Vaccines based on mRNA can be adapted to treat virus variants more easily than traditional vaccines, VTF Interim Chair Clive Dix said.
Price: 116.00, Change: +6.01, Percent Change: +5.46